SCHEMBL15880692

SCHEMBL15880692

C1OCC2CC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276275 0.91
SCHEMBL14355410 0.84
SCHEMBL12163166 0.84
SCHEMBL4223261 0.78
SCHEMBL25449999 0.76
SCHEMBL16878438 0.75
SCHEMBL24024127 0.75
SCHEMBL1636208 0.75
SCHEMBL16878430 0.73
SCHEMBL16878740 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10028942-B2 3-substituted pyrazoles and uses thereof GENENTECH, INC. (US) 2018-07-24 US claimed
EP-2945938-B1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS HOFFMANN LA ROCHE (CH) 2018-03-07 EP claimed
US-20170087137-A1 3-SUBSTITUTED PYRAZOLES AND USES THEREOF GENENTECH, INC. (US) 2017-03-30 US claimed
US-9550777-B2 3-substituted pyrazoles and use as DLK inhibitors GENENTECH, INC. (US) 2017-01-24 US claimed
US-20160002228-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS GENENTECH, INC. (US) 2016-01-07 US claimed
EP-2945938-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-25 EP claimed
WO-2014111496-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-24 WO claimed
WO-2026093741-A1 HETERO-[3.1.1]PROPELLANE COMPOUNDS, SYNTHESIS AND USES THEREOF OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2026-05-07 WO disclosed
EP-4695238-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2026-02-18 EP disclosed
EP-4646411-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2025-11-12 EP disclosed
EP-4646414-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2025-11-12 EP disclosed
EP-4646416-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2025-11-12 EP disclosed
CN-120136870-A GLP-1 receptor targeting compounds and uses thereof 信达生物科技有限公司 2025-06-13 CN disclosed
US-20160297826-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-13 US disclosed
US-9340540-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2016-05-17 US disclosed
US-20160002228-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS GENENTECH, INC. (US) 2016-01-07 US disclosed
EP-2945938-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-25 EP disclosed
US-20150266875-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-24 US disclosed
WO-2015103583-A1 MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-07-09 WO disclosed
WO-2014111496-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-24 WO disclosed